1. Introduction {#s0005}
===============

Choriocarcinoma is characterized by an abnormal proliferation of trophoblastic cells. Choriocarcinoma represents a small subset of gestational trophoblastic neoplasia that originates in villous cells, one of the two lines of trophoblastic differentiation ([@b0005]). Common signs and symptoms of a choriocarcinoma include pelvic pain or pressure, abnormal uterine bleeding, and elevated serum β-human chorionic gonadotropin (β-hCG), but may also have symptoms specific to the location of metastatic disease. Choriocarcinoma is highly aggressive with a well-known tendency to metastasize early via hematogenous spread. Common sites of metastasis include the brain, mediastinum, lung, stomach, pancreas, cervix, and ureter ([@b0005]). As choriocarcinoma invades blood vessels, lesions develop extensive necrosis and parenchymal hemorrhage.

Gestational choriocarcinomas are of fetal trophoblastic origin that can develop in association with abortion, ectopic pregnancy, or an intrauterine pregnancy of any gestational age. In contrast, non-gestational primary choriocarcinomas are exceedingly rare and arise from germ cells in the ovary, with an incidence of 1 in 369,000,000 ([@b0010]).

Some choriocarcinomas are not considered primary malignancies, but rather have de-differentiated from another primary carcinoma. When this occurs, the most common primary site of carcinoma is the upper gastrointestinal tract ([@b0015], [@b0020]).

The process by which gastrointestinal adenocarcinomas de-differentiate to choriocarcinoma is not well understood. The most popular theory suggests that the adenocarcinoma de-differentiates at the cellular level to that of the embryonal ectoderm, acquiring the primary components of trophoblastic tissue ([@b0015], [@b0020]). In this new cell line, de-differentiation proceeds to choriocarcinoma, which classically invades vasculature, resulting in widespread metastases.

Because choriocarcinoma arising from de-differentiated adenocarcinoma is such a rarely diagnosed entity, it is important to document cases and their clinical outcomes for future research and future insights into improved patient care. In this report, we add to the limited collection of confirmed cases of de-differentiated choriocarcinoma \[[Table 1](#t0005){ref-type="table"}\], including a description of the radiographic workup and pathologic assessments.Table 1Previous cases of gastric/esophageal adenocarcinoma de-differentiated to choriocarcinoma.Study Author, YearLocation of GI Adenocarcinomaβ-hCG Elevation?Was it Surgically Excised?Chemotherapy RegimenSurvival[@b0030]EsophagealYesNoCarboplatin, Etoposide, BleomycinDeceased at 19 months[@b0025]EsophagealYesNoChlorambucil, Methotrexate, DactinomycinDeceased at 2 months[@b0035]GastricYesYesTS-1 (titanium silicate) and CDDP (Cisplatin)Alive at 8 months[@b0040]GastricYesYesNot reportedDeceased, unknown longevity[@b0045]GastricYesYesCisplatin, 5-FUDeceased at 6 months

2. Case presentation {#s0010}
====================

A 62-year-old woman presented to the emergency department with a chief complaint of sero-sanguinous drainage from her right eye. She reported a 4-month history of nausea and vomiting, progressive dysphagia, right upper quadrant abdominal pain, constipation, visual changes, and a 50-lb weight loss. She was seen in the outpatient setting by an ophthalmologist and was suspected to have melanoma based on clinical presentation. Brain CT showed a 2.9x3.2x3.0-cm hemorrhagic mass in the left temporo-parietal region with surrounding moderate vasogenic edema with mass effect on the left lateral ventricle \[[Fig. 1](#f0005){ref-type="fig"}A\]. This was better characterized by subsequent MRI \[[Fig. 1](#f0005){ref-type="fig"}C\], showing its hemorrhagic nature as well as multiple other sub-centimeter cerebral metastases. Within the right posterior orbital globe, there was a heterogeneous mass measuring 0.6x1.3x0.6-cm, the likely source of her ocular hemorrhage. Abdominal CT showed multiple liver metastases \[[Fig. 1](#f0005){ref-type="fig"}B\]. While pelvic ultrasound demonstrated two masses in the wall of the uterus, measuring 7.6 × 4.7 × 5.8-cm and 3.5 × 2.9 × 2.6-cm, respectively, these were radiographically consistent with uterine fibroids. The uterus did not show significant hypermetabolism on PET/CT \[[Fig. 1](#f0005){ref-type="fig"}D\], and a recent outpatient D&C revealed benign polyps.Fig. 1Patient imaging.

A chest CT showed a mass in the GE junction involving the distal esophagus and the proximal stomach \[[Fig. 1](#f0005){ref-type="fig"}E\]. There were also several pulmonary metastases and enlarged right hilar lymph nodes.

A craniotomy was performed to relieve intracranial pressure from the mass. Microscopic examination showed a pleomorphic malignant neoplasm with extensive hemorrhage \[[Fig. 2](#f0010){ref-type="fig"}A, B\]. The tumor was negative for melanoma markers and positive for cytokeratin and the preliminary diagnosis was a poorly differentiated metastatic carcinoma. On further characterization, the tumor cells were found to be positive for β-hCG, supporting the diagnosis of choriocarcinoma. This prompted further laboratory investigations that revealed a serum β-hCG of 250,188 mIU/mL and a subsequent working clinical diagnosis of non-gestational choriocarcinoma.Fig. 2Pathology: (A) Low power view of brain mass with extensive hemorrhage and necrosis. (B) High power view of the brain tumor cells with extreme pleomorphism, primitive phenotype with frequent multinucleated cells (recapitulating the syncytiotrophoblast). (C) Brain tumor cells are positive for β-hCG and negative for S100. (D) Biopsy demonstrating normal cardia/lower esophageal mucosa on the left with a poorly differentiated adenocarcinoma on the right upper corner. (E) A β-hCG stain on this GI tissue was negative in the malignant cells. (F) Liver biopsy demonstrates a poorly differentiated malignancy, positive for MOC 31 (G) and β-hCG (H) consistent with metastatic choriocarcinoma.

The patient underwent esophagogastroduodenoscopy (EGD) with biopsy of the GE junction mass revealing poorly differentiated adenocarcinoma \[[Fig. 2](#f0010){ref-type="fig"}D, E\]. Percutaneous liver biopsy showed poorly differentiated carcinoma and β-hCG staining cells, histologically similar to the brain pathology \[[Fig. 2](#f0010){ref-type="fig"}F, G, H\]. With this new information and review of reported cases, the diagnosis became GI primary adenocarcinoma with de-differentiated choriocarcinoma metastases in at least two of the multiple metastatic sites.

The patient was treated with the FOLFOX \[FOL = Leucovorin Calcium (Folinic Acid), F = Fluorouracil, OX = Oxaliplatin\] chemotherapy regimen as it is a recommended first-line regimen for the treatment of advanced adenocarcinoma of the esophagus and GE junction^10^. FOLFOX therapy was decided upon by our multidisciplinary tumor board. One month after the initiation of therapy, the patient's serum β-hCG levels decreased to 140,884 mIU/mL. Unfortunately, the patient's status worsened with transaminitis, multi-organ failure, and sepsis. Imaging showed drastic progression of the liver lesions. The patient discontinued treatment, entered hospice, and died 1.5 months following initiation of treatment.

3. Discussion {#s0015}
=============

This case highlights the potential of divergent differentiation in high-grade, poorly differentiated malignancies and the importance of establishing the correct site of origin in cases of non-gestational choriocarcinoma. The pathologist's role in detecting these divergent histologies can be critical in directing appropriate treatment plans. Had this extensive radiographic and pathologic assessment not been performed sequentially as outlined above, the assumption could have otherwise been that of a primary gynecologic choriocarcinoma.

A limited number of similar cases have been reported that outline the diagnostic evaluation and treatment of a de-differentiated esophageal or gastric adenocarcinoma with choriocarcinoma elements \[[Table 1](#t0005){ref-type="table"}\]. One such report treated with chemotherapy generally used for choriocarcinoma involved a 44-year-old male patient with a 9-cm fungating adenocarcinoma in the lower third of the esophagus, an elevated serum β-hCG and metastases to the lungs, stomach, small intestine, liver, pancreas, spleen, kidneys, brain, and prostate. The primary esophageal lesion was treated with radiation therapy, followed by chlorambucil, methotrexate, and dactinomycin. The lesion initially decreased in size, but after 2 months of treatment the disease progressed and the patient died 62 days after diagnosis ([@b0025]). Autopsy findings of the esophageal mass showed well-differentiated adenocarcinoma with coexisting areas of choriocarcinoma. Biopsy of all other metastatic lesions were consistent with choriocarcinoma.

In another case where a choriocarcinoma chemotherapy regimen was used, a 49-year-old male presented with Barrett's esophagitis and a 20-cm polypoid esophageal mass. The endoscopic biopsy was consistent with poorly differentiated adenocarcinoma and de-differentiated choriocarcinoma. The patient received a carboplatin, etoposide, and bleomycin regimen. The β-hCG normalized and he achieved complete remission within 6 months. However, 10 months later, he relapsed with cerebral metastases and died within 3 months, despite salvage cranial radiation therapy ([@b0030]).

While there is no consensus on optimal treatment for widespread metastatic choriocarcinoma de-differentiated from another primary malignancy, a thorough diagnostic workup is important. The most effective frontline therapy for gastrointestinal adenocarcinomas is a FOLFOX regimen ([@b0050]), whereas primary choriocarcinomas are treated with high-dose methotrexate regimens ([@b0010]). While we are unable to determine how she would have responded to a methotrexate regimen, literature review \[[Table 1](#t0005){ref-type="table"}\] provided in this report would suggest that survival is poor regardless of treatment rendered.

Given the extreme rarity of these cases and inability to conduct clinical trials, there is no established chemotherapy protocol for the treatment of choriocarcinoma arising in GI adenocarcinoma. Given the origin from GI adenocarcinoma and the subsequent de-differentiation to choriocarcinoma, decisions about the specific cytotoxic regimen offered is difficult and exposes a significant research gap for these patients. In addition, molecular differences between gestational choriocarcinoma and choriocarcinoma arising in an adenocarcinoma are unknown. Perhaps future genomic assessments using Next Generation Sequencing (NGS) could aid in diagnosis as well as our understanding of the origins of these cancers, and possible targets for therapy.
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